Molecular identification of the vaccine strain from the inactivated oil emulsion H9N2 low pathogenic avian influenza vaccine by Choi, Jun-Gu et al.
J OURNAL OF
Veterinary
Science Short Communication
J.  Vet.  Sci.  (2010),  11(2),    161򰠏163
DOI:  10.4142/jvs.2010.11.2.161
*Corresponding author
Tel: +82-31-467-1807; Fax:+82-31-467-1814
E-mail: leeyj@nvrqs.go.kr
Molecular identification of the vaccine strain from the inactivated oil 
emulsion H9N2 low pathogenic avian influenza vaccine
Jun-Gu Choi
1, Youn-Jeong Lee
1,*, Ji-Yeon Kim
1, Yeon-Hee Kim
1, Mi-Ra Paek
1, Dong-Kun Yang
1, Seong-Wan 
Son
1, Jae-Hong Kim
2
1National Veterinary Research and Quarantine Service, Anyang 430-757, Korea
2College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea
  In order to control the H9N2 subtype low pathogenic avian 
influenza (LPAI), an inactivated vaccine has been used in 
Korea since 2007. The Korean veterinary authority permitted 
the use of a single H9N2 LPAI vaccine strain to simplify the 
evolution of the circulating virus due to the immune pressure 
caused  by  the  vaccine  use.  It  is  therefore  important  to 
determine the suitability of the vaccine strain in the final 
inactivated oil emulsion LPAI vaccine. In this study, we 
applied molecular rather than biological methods to verify 
the suitability of the vaccine strain used in commercial vaccines 
and  successfully  identified  the  strain  by  comparing  the 
nucleotide sequences of the hemagglutinin and neuraminidase 
genes with that of the permitted Korean LPAI vaccine strain. 
It is thought that the method used in this study might be 
successfully applied to other viral genes of the LPAI vaccine 
strain and perhaps to other veterinary oil emulsion vaccines.
Keywords:  H9N2 avian influenza, identification of vaccine 
strain, oil emulsion vaccine
The H9N2 low pathogenic avian influenza (LPAI) has 
become a serious problem in the poultry industry worldwide 
[2,6] and concerns about a possible zoonotic disease have 
been raised [8].
Since 2007, the Korean veterinary authority has permitted 
the use of inactivated H9N2 LPAI vaccine to control the 
disease and has decided to use a single strain to simplify the 
antigenic variation of the H9N2 LPAI virus which is 
circulating in the country [3]. It is therefore necessary to 
eliminate any possibility that the vaccine has been unin-
tentionally contaminated during production or that it has, 
without permission, been deliberately altered by other 
vaccine strains (e.g. autogenous vaccines) to achieve better 
efficacy. 
However, it is difficult to identify the strain through biological 
(serological) methods, because the strain most antigenically 
similar to other circulating pathogens has been chosen as the 
vaccine strain. In addition, antigen extraction is difficult, 
particularly in inactivated oil emulsion vaccines due to the 
stability of the emulsion. The same situation exists with the 
Korean H9N2 LPAI vaccine [3]. 
To overcome these limitations, we used isopropyl myristate 
(IPM) to separate the antigen from the oil adjuvant according 
to the method employed by Maas et al. [7]. We then applied 
molecular methods to detect genetic characteristics of the 
Korean H9N2 LPAI vaccine strain through conventional 
reverse transcription-polymerase chain reaction (RT-PCR) 
and direct nucleotide sequencing. 
The H9N2 subtype LPAI viruses used in this study for 
comparing the nucleotide sequences of viral genes:were A/ 
chicken/Korea/01310/2001 (CE3; 01310/CE3) (CE number 
represents the passage number through the chicken embryo), 
a parent virus of the Korean H9N2 LPAI vaccine strain; 
A/chicken/Korea/01310/2001 (CE20; 01310/ CE20), a vaccine 
strain; A/chicken/Korea/Q30/2004 (CE2; Q30/04), A/chicken/ 
Korea/Q99/2006 (CE1; Q99/ 06), A/Duck/Korea/GJ84/ 
2007 (CE1; GJ84/07), and A/chicken/Korea/ GJ180/2008 
(CE1; GJ180/08), recent field isolates [3,5]. All viruses were 
propagated in 9-11 day old specific pathogen free embryonated 
chicken eggs (ECE) via the allantoic cavity. Commercial 
H9N2 LPAI vaccines produced by 5 Korean vaccine companies 
were used. All vaccines used formalin as an inactivating 
agent and were emulsified with mineral oil adjuvant.
Viral RNA from infectious allantoic fluids and IPM treated 
antigens were extracted with the Viral Gene-spin Viral DNA/ 
RNA Extraction Kit (iNtRON Biotechnology, Korea). RT- 
PCR was done with the AccuPower RT/PCR Premix Kit 
(Bioneer, Korea) according to the manufacturer’s directions. 
Amplified fragments were visualized using a 1.5% agarose 
gel electrophoresis with ethidium bromide staining. 
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Fig. 1. Comparison of the nucleotide sequences of the hemagglutinin (A) and neuraminidase (B) genes of the vaccine parental strain
(01310/CE3), vaccine strain (01310/CE20), five commercial LPAI vaccines (vaccine A to E), and representative Korean H9N2 LPAI
viruses (field isolates). The GenBank accession number for the hemagglutinin and neuraminidase genes of A/chicken/Korea/MS96/ 
1996 (MS96/96) are AF203008 and AF203786, respectively. Q99/06, GJ84/07 and GJ180/08 were sequenced in this study. Dots 
indicate residues identical to 01310/CE3 and dashes stand for missing nucleotides. The primer sequences are indicated with italic bold
fonts. Nucleotide sequences for the additional potential N-linked glycosylation site are indicated with underlines.
influenza viruses are surface glycoproteins and act as major 
immunogenic antigens. Therefore, we focused on these two 
genes in identifying the vaccine strain through RT-PCR 
and direct nucleotide sequencing.
The high growth rate of the Korean H9N2 LPAI vaccine 
strain in chicken eggs is achieved by performing over 20 serial 
blind passages with the parent virus through the ECE [3]. 
During each passage the virus acquires nucleotide changes 
in the HA and NA genes which lead to an additional potential 
N-linked glycosylation site near the receptor binding site of 
HA and to an eighteen amino acid deletion in the NA stalk 
region [3]. Therefore, we amplified the 204 bp region of the 
HA gene, including the additional potential glycosylation 
site in the vaccine strain. For the NA gene, primers were 
designed to check the 54 bp deletion in the NA stalk region 
of the vaccine strain. The amplified product sizes are 127 bp 
for the vaccine strain and 181 bp for the parent and field 
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To determine the specificity of the primer sets to the Korean 
H9N2 LPAI vaccine virus, we used 3 type A influenza 
viruses (01310/CE20, A/Puerto Rico/8/1934 (H1N1, PR/8) 
and A/Chicken/Korea/IS/2006 (H5N1, IS/06), Newcastle 
disease virus (NDV, LaSota) and infectious bronchitis virus 
(IBV, M41). The primer sets for the HA and NA genes reacted 
only to the 01310/CE20 but not to the other influenza 
viruses, NDV or IBV. The amplified products for the HA and 
NA gene specific primer sets were 204 bp and 127 bp, 
respectively (data not shown). For the sensitivity of the 
primer sets, we performed RT-PCR with 10-fold serially 
diluted 01310/CE20 (10
8.8EID50/0.1 mL). The HA and NA 
gene primer sets could detect the virus to dilution factors of 
10
-7 (10
1.8EID50/0.1 mL) and 10
-6 (10
2.8 EID50/0.1 mL), 
respectively (data not shown).
With this specificity and sensitivity data, we attempted to 
apply the primer sets to the commercial H9N2 AI vaccines 
(monovalent) from 5 Korean vaccine companies. As a result, 
we successfully obtained 204 bp fragments from the viruses 
and vaccine samples for the HA gene. In the NA gene, we 
could differentiate the vaccine strain from the parent virus 
and the recent field isolate by size through agarose gel 
electrophoresis. The 181 bp region of the NA gene was 
amplified from 01310/CE3 and Q30/04, and the smaller 127 
bp fragment from 01310/CE20, and the extracted antigens 
from all of the five commercial inactivated H9N2 LPAI 
vaccines (data not shown).
The amplified fragments were sequenced using ABI 
PRISM BigDye Terminator Cycle Sequencing Kits 
(Applied Biosystems, USA) with ABI PRISM 3730XL 
Analyzer (Applied Biosystems, USA). The nucleotide 
sequences were aligned with the Clustal W algorithm 
packaged in the BioEdit program (version 7.0.9.0.; North 
Carolina State University, USA).
The HA and NA gene sequences of the amplified fragments 
of the extracted antigens from the vaccines were identical 
to the vaccine strain (01310/CE20) and were distinguishable 
from parent and other Korean isolates (Figs. 1A and B). We 
also found the additional potential N-linked glycosylation 
site in HA genes and the 54 bp deletion in NA genes of the 
extracted antigens; these findings are characteristic of the 
Korean H9N2 LPAI vaccine strain [3]. 
We next tested the practical applicability of this assay with 
a total of 19 commercial LPAI (H9N2) inactivated oil emulsion 
vaccines, which were produced by 5 Korean vaccine 
companies. Six monovalent, 5 bivalent (for LPAI and ND), 
6 tetravalent (for LPAI, ND, American and Korean type IB), 
and 2 pentavalent (for LPAI, ND, American and Korean type 
IB, and egg drop syndrome) vaccines were tested. 17 of the 
vaccines had been stored for less than 9 months, 1 for over 
15 months and 1 for over 18 months from the date of 
manufacture.  We were able to obtain appropriately sized 
amplicons from all 19 vaccines with the primer sets (data not 
shown) and this strongly supported the practical usefulness 
of the method.
We successfully amplified genes of the antigens extracted 
from oil emulsified vaccines treated with formalin. However, 
other inactivating agents, such as beta propiolactone and 
binary ethylenimine, have been used for inactivated vaccines 
[1,4] and their mode of action is different than that of 
formalin [1,9]. Therefore, further study is needed to elucidate 
the applicability of this method to vaccines inactivated with 
other agents.
Although the amplified regions targeted in this study are 
relatively short and limited to only the HA and NA genes, 
this method may be an efficient tool for identifying the 
properly licensed H9N2 LPAI vaccine in Korea and might 
be applied to other genes of the vaccine strain or to other 
vaccines in other countries.
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